[{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Iambic Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Iambic Therapeutics \/ Revolution Medicines","highestDevelopmentStatusID":"3","companyTruncated":"Iambic Therapeutics \/ Revolution Medicines"}]

Find Technology Clinical Drug Pipeline Developments & Deals by Iambic Therapeutics

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          APGA Annual Conference
                          Not Confirmed
                          APGA Annual Conference
                          Not Confirmed

                          Details : Through the collaboration Iambic will use structures and molecular libraries provided by Revolution Medicines to pursue novel drug candidates using Iambic’s leading AI models.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          July 09, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Revolution Medicines

                          Deal Size : $25.0 million

                          Deal Type : Collaboration

                          blank